Urology Research & Practice
Editorial

Changes in patients’ quality of life following treatment of localized and metastatic prostate cancer

1.

Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, İstanbul

Urol Res Pract 2011; 37: 184-190
Read: 1097 Downloads: 875 Published: 25 July 2019

Abstract

Objective: In this study, we aimed to evaluate the change of quality of life of patients with localized and metastatic prostate cancer after treatment.

Materials and methods: Twenty-eight patients (mean age 62.45±7.11 years) who were treated with radical prostatectomy and 14 patients (mean age 69.94±8.39 years) who were treated with orchioectomy between December 2007 and June 2010 were included in the study. Patients were asked to complete EORTC QOL-30 instrument before (T0) and 1st (T1), 3rd (T2), 6th (T3), and 12th (T4) months after the treatment. QOL-C30 scores were calculated and converted to 0-100 scale. Score changes of QOL-C30 were the change in scores of related time period from basal score (T1-T0, T2-T0, T3-T0, and T4-T0). Optimum time to evaluate quality of life was defined by determining the score which was closest to the basal score. In addition, the affected quality of life parameters were determined. 

Results: The mostly affected parameter was the social functioning in radical prostatectomy group. Quality of life got worse in each time period. Total quality of life was the most affected parameter in orchioectomy group. Quality of life significantly increased in first month measurement, and this increase continued in 3rd, 6th, and 12th months. In both groups, quality of life deteriorated from baseline mostly in 1st month after the treatment. Quality of life was closest to the basal values in 12th month measurements.

Conclusion: Patients’ quality of life should be assessed at 3rd month following treatment of localized and metastatic prostate cancer. Although quality of life of metastatic prostate cancer patients was initially worse than that of localized prostate cancer patients, improvement of quality of life in patients with metastatic cancer was more obvious.

Files
EISSN 2980-1478